CIK 0001880438
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 820606654
- Phone
- +1 650-331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- 4 Grant or award Eizen Joshua M acquired 58,500 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 145,250 shares (grant or award)
- 4 Grant or award Chief Strategy Officer acquired 28,000 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 2,957 shares at $1.34 ($3,965)
- 4 Open-market sale Chief Development Officer sold 2,957 shares at $1.34 ($3,965)
- 4 Open-market sale Chief Strategy Officer sold 2,029 shares at $1.34 ($2,721)
- 4 Open-market sale Eizen Joshua M sold 9,663 shares at $1.34 ($12,958)
- 4 Grant or award Director acquired 3,166 shares (grant or award)
- 4 Grant or award Director acquired 8,972 shares (grant or award)
- 4 Grant or award Director acquired 8,972 shares (grant or award)
- 4 Grant or award Director acquired 9,816 shares (grant or award)
- 4 Grant or award Director acquired 9,077 shares (grant or award)
- 4 Open-market buy Director bought 60,000 shares at an average $1.45 ($86,708)
- 4 Open-market buy Director bought 75,000 shares at an average $1.41 ($105,685)
- 4 Open-market buy Director bought 2,000 shares at $1.40 ($2,800)
- 4 Open-market buy Director bought 200,000 shares at an average $1.07 ($213,128)
- 4 Open-market buy Director bought 25,000 shares at an average $1.00 ($25,046)
- 4 Open-market buy Chief Executive Officer bought 50,000 shares at $1.00 ($49,970)
- 4 Grant or award Chief Strategy Officer acquired 10,125 shares (grant or award)
- 4 Grant or award Eizen Joshua M acquired 31,500 shares (grant or award)
Page 5 of 11 · 216 filings